307 related articles for article (PubMed ID: 34123863)
21. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
22. Proteomics strategies for urothelial bladder cancer diagnosis, prognosis and treatment: Trends for tumor biomarker sources.
Tabaei S; Haghshenas MR; Webster TJ; Ghaderi A
Anal Biochem; 2023 Apr; 666():115074. PubMed ID: 36738874
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
24. Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.
Zhao M; Huang H; He F; Fu X
Front Immunol; 2023; 14():1188277. PubMed ID: 37275909
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
26. Single-cell sequencing technologies in bladder cancer research: Applications and challenges.
Lyu T; Lin Y; Wu K; Cao Z; Zhang Q; Zheng J
Front Genet; 2022; 13():1027909. PubMed ID: 36338973
[TBL] [Abstract][Full Text] [Related]
27. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
Aoun F; Rassy EE; Assi T; Albisinni S; Katan J
Immunotherapy; 2017 Mar; 9(5):451-460. PubMed ID: 28357911
[TBL] [Abstract][Full Text] [Related]
28. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
29. Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer.
Yang L; Li A; Liu F; Zhao Q; Ji S; Zhu W; Yu W; Zhang R; Liu Y; Li W; Zhang Y
Front Cell Dev Biol; 2021; 9():596484. PubMed ID: 33777927
[TBL] [Abstract][Full Text] [Related]
30. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
31. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
[TBL] [Abstract][Full Text] [Related]
32. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
33. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
Wan Z; Wang Y; Li C; Zheng D
Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
[TBL] [Abstract][Full Text] [Related]
34. Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
Caramelo B; Zagorac S; Corral S; Marqués M; Real FX
Eur Urol Oncol; 2023 Aug; 6(4):366-375. PubMed ID: 36890105
[TBL] [Abstract][Full Text] [Related]
35. Adaptive Immunity in Genitourinary Cancers.
Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
[TBL] [Abstract][Full Text] [Related]
36. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
Sun H; Sun C
Front Immunol; 2019; 10():2354. PubMed ID: 31681269
[TBL] [Abstract][Full Text] [Related]
37. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors.
Kalkusova K; Smite S; Darras E; Taborska P; Stakheev D; Vannucci L; Bartunkova J; Smrz D
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232398
[TBL] [Abstract][Full Text] [Related]
38. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
39. The Tumor Microenvironment of Bladder Cancer.
Hatogai K; Sweis RF
Adv Exp Med Biol; 2020; 1296():275-290. PubMed ID: 34185299
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.
Chiang RS; Glover MJ; Khaki AR; Srinivas S
Onco Targets Ther; 2022; 15():1259-1269. PubMed ID: 36275184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
